Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice

Area of Science:

• Cell Biology
• Skeletal Biology
• Pharmacology

Background:

• Osteoclasts (OCs) are crucial for bone remodeling, and their dysregulation contributes to skeletal disorders.
• The RANK signaling pathway is essential for osteoclast differentiation and function.
• Targeting RANK is a potential therapeutic strategy, but its broad involvement necessitates selective approaches.

Purpose of the Study:

• To develop and evaluate a novel cell-permeable inhibitor, RANK receptor inhibitor (RRI), targeting a specific cytoplasmic motif of RANK.
• To assess RRI's efficacy in inhibiting osteoclast formation, function, and downstream signaling.
• To investigate RRI's therapeutic potential in preclinical models of bone loss.

Main Methods:

• Development of a peptide inhibitor (RRI) targeting a specific RANK cytoplasmic motif.
• In vitro assessment of RRI on RANKL-induced osteoclast formation and resorptive function using murine bone marrow-derived macrophages.
• In vivo evaluation of RRI in mouse models of inflammation-induced bone destruction and ovariectomy-induced bone loss.

Main Results:

• RRI peptide successfully blocked RANKL-induced osteoclast formation and inhibited osteoclast resorptive function.
• RRI treatment induced osteoclast apoptosis and disrupted the actin cytoskeleton.
• The inhibitor impaired downstream RANK signaling pathways involving Vav3, Rac1, and Cdc42.
• RRI demonstrated efficacy in preventing bone loss in both inflammation and ovariectomy-induced mouse models.

Conclusions:

• The RANK receptor inhibitor (RRI) selectively targets a key motif in RANK, effectively inhibiting osteoclastogenesis and function.
• RRI shows promise as a therapeutic agent for osteoporosis and other bone diseases characterized by excessive bone resorption.
• Targeting specific RANK motifs offers a strategy for developing selective therapies with potentially fewer side effects.